Aspirin plus omega-3 for gum disease — but why might it help some ADULTS with autism? Back to resolvins and FPR2

 

 

Sometimes the most interesting autism research isn't about autism.

One of the reasons I continue to read research far outside the autism field is that biology does not respect the boundaries between medical specialties.

A discovery in Alzheimer's disease can reveal something important about autism.

A mitochondrial study can suggest a new autism hypothesis.

Research into probiotics can uncover an unexpected signalling pathway.

And sometimes you have to read about gum disease.

A new clinical trial in severe periodontitis has caught my attention because it provides an intriguing piece of human evidence for a therapeutic concept I discussed in my recent post on FPR2 and inflammation resolution.

 

Epiphany: Edging closer to targeting neuro-inflammation in autism via FPR2

There is also already some autism-specific evidence involving both omega-3 and aspirin individually.

The interesting question is what happens when they are put together.

 

A brief recap of the FPR2 idea

In my recent post, I discussed a potentially important shift in how we think about neuroinflammation in autism.

Rather than simply trying to suppress inflammation, researchers are increasingly interested in the body's own mechanisms for resolving inflammation and returning tissue to a healthy state.

One of the key players is FPR2, a receptor found on immune cells as well as microglia, astrocytes, neurons and other cells in the brain.

FPR2 can be activated by naturally occurring specialized pro-resolving mediators, including Lipoxin A4 (LXA₄) and certain resolvins.

This was particularly interesting in autism because one study found lower levels of LXA₄ in children with autism, with lower levels associated with greater autism severity in that particular study.

I also discussed a new experimental drug called MR-39, which directly activates FPR2. In autism mouse models, MR-39 reduced inflammatory signalling and was associated with improvements in synaptic proteins, dendritic spine structure and social behaviour.

The important idea was therefore not simply:

"Autism involves too much inflammation."

It was:

"Could some autistic people have difficulty switching inflammation off properly?"

If so, stimulating the body's natural resolution-and-repair system might be a more sophisticated approach than simply suppressing inflammatory pathways.

At the time, MR-39 was an experimental research compound and there was no obvious practical way to activate FPR2 safely in humans.

But there may be another way of approaching the same biological system.

And this is where an unexpected paper about gum disease becomes interesting.

 

An unexpected discovery from dentistry

The new study was a multicentre randomized clinical trial involving 109 people with advanced periodontitis.

All participants received standard mechanical treatment to remove bacterial deposits beneath the gums.

They were then randomized to receive placebo, antibiotics, omega-3 plus low-dose aspirin, or both treatments.

The antibiotic group received amoxicillin and metronidazole for two weeks.

The omega-3 group received 3 grams of omega-3 per day plus 100 mg of aspirin per day for six months.

The patients were followed for a full year.

The researchers defined treatment success as having no more than four remaining deep periodontal pockets.

In everyday language, the results mean that roughly 6 out of every 10 people receiving antibiotics improved enough to reach the study's target.

But almost exactly the same proportion of people taking omega-3 plus aspirin reached the target.

The actual figures were:

• Antibiotics: 58.6%
• Omega-3 + aspirin: 57.7%
• Antibiotics + omega-3/aspirin: 57.1%
• Placebo + mechanical treatment: 23.1%

So about 6 people in 10 reached the target with antibiotics, compared with almost 6 in 10 taking omega-3 plus aspirin, while only about 2 in 10 reached it with mechanical treatment alone.

This does not mean that omega-3 and aspirin are antibiotics.

They aren't.

What is interesting is that the two approaches produced a similar clinical outcome while acting through very different biology.

 

The body has its own inflammation-resolution system

This brings us back to the FPR2 story.

We often think of inflammation as something that should simply be switched off.

But the biology is more sophisticated than that.

Inflammation is useful.

When tissue is damaged or invaded by microbes, the immune system needs to respond. The problem arises when the inflammatory response persists after the original danger has been dealt with.

The body therefore has an active system for resolving inflammation.

Specialized pro-resolving mediators, or SPMs, help coordinate this process.

They include:

• lipoxins
• resolvins
• protectins
• maresins

These molecules do not simply suppress the immune system.

They help tell it:

"The job is done. Stop fighting and start repairing."

That distinction is important.

The goal is to allow the inflammatory response to finish properly.

 

Omega-3 is already an interesting molecule in autism

It is important to make clear that omega-3 is not a new idea in autism.

There have been numerous studies investigating EPA and DHA in people with autism or ADHD. The clinical results have been inconsistent, so omega-3 cannot currently be regarded as an established treatment for the core characteristics of autism.

Nevertheless, there are several reasons why researchers have been interested in it.

EPA and DHA have important roles in the brain and are also precursors for specialized pro-resolving mediators.

So omega-3 is potentially doing something more interesting than simply acting as a conventional "anti-inflammatory."

It provides some of the raw material from which the body's inflammation-resolution system makes its signalling molecules.

Aspirin is also not a completely new idea

Aspirin is not being introduced here as an entirely new autism treatment either.

A 2024 study investigated chronic low-dose aspirin in rats exposed prenatally to valproic acid, an established animal model used to produce autism-like behaviours.

The researchers reported that aspirin:

• improved social behaviour
• reduced repetitive grooming
• reduced anxiety-like behaviour
• increased AMPK activity in the hippocampus.

The study therefore provides an autism-specific experimental reason to be interested in aspirin, although obviously a rat study cannot establish that aspirin improves autism in humans.

AMPK is particularly interesting because it is one of the cell's major energy sensors and regulates processes involved in cellular energy metabolism, mitochondrial function, autophagy and cellular stress responses.

So aspirin already has an independent connection to autism research.

 

So what is new?  The interesting part is the combination

What interests me is the specific biological reason for combining them.

And that reason comes directly from the FPR2 hypothesis discussed in my previous post.

 

Omega-3 provides the ingredients

EPA and DHA are precursors for several specialized pro-resolving mediators.

But aspirin introduces an additional biochemical effect.

Aspirin can modify the activity of COX enzymes and redirect some lipid metabolism towards aspirin-triggered specialized pro-resolving mediators.

These include aspirin-triggered forms of resolvins.

Some of these resolution signals can activate FPR2.

This gives us a potential sequence:

 

This is why the combination is more interesting than either component considered in isolation.

The hypothesis is not simply:

"Omega-3 is anti-inflammatory, so perhaps it helps autism."

It is much more specific:

"If impaired inflammation resolution is relevant to a subset of autistic people, could omega-3 plus aspirin increase endogenous pro-resolving signalling and thereby activate pathways such as FPR2?"

That is a testable biological hypothesis.

This connects directly to my previous FPR2 post

In my previous post I discussed research reporting lower circulating Lipoxin A4 (LXA₄) in children with autism, with lower LXA₄ associated with greater autism severity in that particular study.

LXA₄ is itself a specialized pro-resolving mediator and an important FPR2 ligand.

I also discussed the experimental FPR2 agonist MR-39.

MR-39 attempts to activate the resolution system directly through FPR2.

The omega-3/aspirin approach would be different.

Rather than directly activating FPR2 with a synthetic drug, it would attempt to increase the body's own production of pro-resolving signals upstream.

So there are now two conceptually different approaches to the same biological system:

MR-39 → direct FPR2 activation

versus

omega-3 + aspirin → increased pro-resolving lipid mediator production → FPR2 and related pathways

 

The latter is obviously much less specific than a dedicated FPR2 agonist.

But biologically, the two ideas converge.

 

Why might this matter to some autistic adults?

A treatment given during early brain development is not necessarily going to have the same effect in an adult.

However, the fact that autism is developmental does not mean that all associated biological abnormalities become permanently fixed once development ends.

An autistic adult can still have differences in:

• immune signalling
• microglial activity
• mitochondrial function
• cellular energy metabolism
• synaptic plasticity
• inflammatory signalling.

If persistent neuroinflammation or metabolic stress is present in a particular person, it is conceivable that changing that biology could improve how the existing neural network functions.

It might mean improving particular domains of function.

For example:

executive function

cognitive flexibility

social engagement

repetitive behaviour

Whether this actually happens in humans remains unknown.

 

Perhaps omega-3 alone is not the whole story

There have already been numerous studies of omega-3 supplementation in autism.

The inconsistent results are interesting.

Perhaps simply supplying more EPA and DHA is not sufficient.

The important question might instead be:

Can the individual efficiently convert those fatty acids into the pro-resolving mediators needed to terminate inflammation?

If the bottleneck is downstream of the fatty acid itself, increasing omega-3 intake may have limited effects.

Aspirin could potentially change the metabolic pathway and increase formation of certain aspirin-triggered pro-resolving mediators.

The dental study provides an important human clue

This is where the periodontitis trial becomes relevant.

The researchers were not trying to treat autism.

They were trying to treat severe gum disease.

Yet omega-3 plus low-dose aspirin produced a clinical result remarkably similar to the antibiotic treatment.

That does not prove anything about autism.

Periodontal inflammation and neuroinflammation are obviously not the same thing.

But it does provide human evidence that manipulating the body's resolution pathways can produce a substantial clinical effect in a chronic inflammatory disease.

That makes the underlying concept more interesting.

And the fact that the treatment did not appear to provide additional benefit when simply added to antibiotics is also intriguing.

The omega-3/aspirin intervention was not just acting as another antibiotic.

It appears to have been addressing a different part of the disease process.

 

Who might respond?

I would not expect every autistic person to respond.

If the mechanism is correct, the likely responders might be people with some combination of:

• persistent inflammatory signalling
• altered immune regulation
• oxidative or metabolic stress
• impaired inflammation resolution
• altered lipid mediator profiles.

That immediately suggests a precision-medicine approach.

Rather than giving the treatment to everybody with an autism diagnosis, identify people whose biology suggests that this particular pathway is abnormal.

 

An important warning about aspirin

There is an obvious reason to be cautious here.

Aspirin is a drug, not a nutritional supplement.

It affects platelet function and can increase bleeding risk. It also has important age-specific safety considerations.

In particular, aspirin should not routinely be given to children or teenagers because of the risk of Reye's syndrome associated with aspirin exposure during certain viral illnesses.

The discussion here is therefore particularly relevant to the question of adult autism, and even there it remains a research hypothesis rather than a treatment recommendation.

 

Why reading outside autism matters

This is perhaps the most important lesson from this whole exercise.

The autism research gave us one piece:

reduced LXA₄ and the possibility of impaired resolution

The FPR2 research gave us another:

direct activation of an inflammation-resolution receptor can improve inflammatory and synaptic abnormalities in autism animal models.

The aspirin/autism animal study gave us another:

low-dose aspirin can alter AMPK signalling and improve autism-like behaviours in rats.

And then a group of researchers studying gum disease unexpectedly supplied another:

omega-3 plus low-dose aspirin can produce a clinical outcome comparable to antibiotics in severe periodontal disease.

But biology does not care whether a paper is published in a dental journal, an autism journal, a neuroscience journal or a mitochondrial journal.

The same molecules and signalling pathways operate across different diseases.

This is why I think anyone seriously interested in autism needs to read far beyond autism research.

Occasionally, it is in a paper about gum disease!

For the moment, I would regard omega-3 plus low-dose aspirin as an intriguing hypothesis for a subset of autistic adults, not as an established autism treatment.

But given the existing evidence for omega-3, the experimental evidence for aspirin, the FPR2/LXA₄ hypothesis, and now the unexpected human findings in periodontitis, I think it is a hypothesis worth testing if you want an OTC anti-inflammatory therapy.